MiMedx Group, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsMiMedx Group is a wound care and surgical biologics company transitioning from placental allografts to a broader portfolio amid Medicare reimbursement headwinds.
What they do
MiMedx develops and commercializes advanced wound care and surgical products, primarily human placental allografts processed via its PURION process, and has expanded into xenografts and other modalities. Its product portfolio includes sheet grafts (AMNIOFIX, AMNIOEFFECT), particulate products (HELIOGEN), and distributed products like RegenKit, NovaForm, G4Derm Plus, and Hydrelix. The company sells primarily in the U.S. across wound care, burn, and surgical specialties.
Revenue drivers
- Surgical products — Largest and fastest-growing segment; Q2 2026 sales of $39.3M, up 15.1% YoY, driven by AMNIOFIX, AMNIOEFFECT, and particulate portfolio.
- Wound products — Declining segment; Q2 2026 sales of $25.1M, down 61.1% YoY due to Medicare reimbursement changes effective January 1, 2026.
- Distribution agreements — Added exclusive distribution deals (e.g., G4Derm Plus via Summit Products Group) to expand portfolio and drive surgical growth.
Recent performance
Q2 2026 net sales were $64.4M, down 34.7% YoY from $98.6M, with a GAAP net loss of $14.8M versus net income of $9.6M in the prior year. Gross margin fell to 69.0% from 81.1% due to lower wound pricing and higher manufacturing costs. The company ended Q2 2026 with $135.8M cash and $15.7M long-term debt. Full-year 2025 revenue was $418.6M with net income of $48.6M.
Strategy
Management is expanding the Surgical portfolio, launching new products, and pursuing inorganic growth, including the announced acquisition of Sanara MedTech. They implemented a reduction-in-force and cost initiatives to align costs with current market conditions. The company is also returning capital to shareholders via a Share Repurchase Plan, repurchasing ~$13M in Q2 2026. They aim to emerge stronger from the reimbursement-driven transition in wound care.
Risks
- Medicare reimbursement changes — January 1, 2026 Medicare changes have cut wound product pricing and volumes, causing a 61% YoY sales decline in Q2 2026.
- Customer credit deterioration — Higher bad debt expense of $5M YoY in Q2 2026 due to credit deterioration of legacy customers.
- Regulatory and supply chain — All U.S. products are FDA-regulated; reliance on donor tissue supply and third-party manufacturers for some allografts and xenografts.
- Integration and acquisition risk — The pending Sanara MedTech acquisition carries execution and integration risks that could dilute focus or strain finances.
Outlook
Management reiterated full-year 2026 net sales guidance of $260-290 million on a standalone basis, expecting a path back to profitability in H2 2026. They noted sequential wound volume growth of 22% in Q2 2026 and expect continued shift toward hospital outpatient settings. The company plans to complete the Sanara MedTech acquisition to accelerate long-term growth.